Back to the news

OncoDNA has inked a distribution agreement with BioHisto Maroc

OncoDNA, the Cancer Theranostic Company, said today that it has inked a distribution agreement with BioHisto Maroc, a company offering a wide range of high-quality clinical, anatomic pathology, molecular testing services to meet diagnostic and treatment planning requirements. BioHisto Maroc will market and distribute OncoDNA’s solutions to oncologists and their patients in Morocco.

Moroccan oncologists will have access to a state-of-the-art molecular profiling program that combines liquid and solid biopsies analyses aspiring to improve the lives of patients with metastatic cancer. Patients will benefit from a personalized medicine based on the most comprehensive tumour profiling solution.

“We are continuing the expansion of our distributor network, with strong background in oncology. BioHisto Maroc is the right partner to promote our solutions in Morocco. Local clinicians can rely on the combined expertise of BioHisto Maroc and OncoDNA to provide their patients with the most efficient care, and hopefully a prolonged life in better health conditions”, says Fiona Demol, International Business Development Manager at OncoDNA.

“This agreement enables us to complete our product offering to oncologists with an extensive range of high-quality molecular diagnostic solutions. We are pleased to work with OncoDNA to offer their cutting edge advanced solutions to Moroccan patients.” says Iman Alaoui Ismaili, General manager at BioHisto Maroc.

If you are a medical doctor from the region and you would like to discuss about a collaboration, please contact OncoDNA’s local coordinator: Mrs. Alaoui Ismaili,

About BioHisto Maroc

BioHisto Maroc Holding is a young and innovative service company created in 2016 specialized in biotechnology. It offers various technical solutions and provides a global support for biology and pathology laboratories in the Moroccan kingdom and on the African continent. BioHisto Maroc offers to pathologists and oncologists through its subsidiaries, to access innovative tests in oncology and tumorous pathology and achieve optimal results, always in the interest of patients.

More information at